Avery RL[au] - Search Results

Year	Number of Results
1986	1
1990	1
1992	1
1993	1
1994	1
1995	2
1996	1
1998	1
2000	2
2004	1
2005	1
2006	8
2007	5
2008	4
2009	1
2010	1
2011	2
2012	2
2013	3
2014	4
2015	6
2016	4
2017	2
2018	1
2019	4
2020	2
2021	2
2022	2
2023	0

1

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.

Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Maia M, Van Everen S, Le K, Hanley WD. Avery RL, et al. Retina. 2017 Oct;37(10):1847-1858. doi: 10.1097/IAE.0000000000001493. Retina. 2017. PMID: 28106709 Free PMC article. Clinical Trial.

2

Retinal non-perfusion in diabetic retinopathy.

Wykoff CC, Yu HJ, Avery RL, Ehlers JP, Tadayoni R, Sadda SR. Wykoff CC, et al. Among authors: avery rl. Eye (Lond). 2022 Feb;36(2):249-256. doi: 10.1038/s41433-021-01649-0. Epub 2022 Jan 11. Eye (Lond). 2022. PMID: 35017700 Free PMC article. Review.

3

Diagnostic and Therapeutic Challenges.

Chen L, Bai X, Avery RL. Chen L, et al. Among authors: avery rl. Retina. 2021 Feb 1;41(2):454-458. doi: 10.1097/IAE.0000000000002664. Retina. 2021. PMID: 31599794 No abstract available.

4

Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern.

Avery RL. Avery RL. J AAPOS. 2009 Aug;13(4):329-31. doi: 10.1016/j.jaapos.2009.06.003. J AAPOS. 2009. PMID: 19683181 No abstract available.

5

Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.

Dhoot DS, Avery RL. Dhoot DS, et al. Among authors: avery rl. Curr Diab Rep. 2016 Dec;16(12):122. doi: 10.1007/s11892-016-0825-4. Curr Diab Rep. 2016. PMID: 27766582 Review.

6

Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity.

Enríquez AB, Avery RL, Baumal CR. Enríquez AB, et al. Among authors: avery rl. Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368. doi: 10.1097/APO.0000000000000302. Asia Pac J Ophthalmol (Phila). 2020. PMID: 32694348 Review.

7

What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

Avery RL. Avery RL. Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i7-10. doi: 10.1136/bjophthalmol-2013-303844. Epub 2013 Dec 10. Br J Ophthalmol. 2014. PMID: 24326326 Free PMC article. Review.

8

Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration.

Kashani AH, Lebkowski JS, Hinton DR, Zhu D, Faynus MA, Chen S, Rahhal FM, Avery RL, Salehi-Had H, Chan C, Palejwala N, Ingram A, Dang W, Lin CM, Mitra D, Martinez-Camarillo JC, Bailey J, Arnold C, Pennington BO, Rao N, Johnson LV, Clegg DO, Humayun MS. Kashani AH, et al. Among authors: avery rl. Stem Cell Reports. 2022 Mar 8;17(3):448-458. doi: 10.1016/j.stemcr.2022.01.001. Epub 2022 Feb 3. Stem Cell Reports. 2022. PMID: 35120620 Free PMC article. Clinical Trial.

9

Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?

Avery RL. Avery RL. J AAPOS. 2012 Feb;16(1):2-4. doi: 10.1016/j.jaapos.2011.11.002. Epub 2012 Jan 10. J AAPOS. 2012. PMID: 22237669 No abstract available.

10

Diagnostic and therapeutic challenges.

Murakami Y, Kusaka S, Oshima Y, Tano Y, Avery RL, Pieramici DJ, Arevalo JF. Murakami Y, et al. Among authors: avery rl. Retina. 2008 Oct;28(9):1357-60. doi: 10.1097/IAE.0b013e318181b923. Retina. 2008. PMID: 19430394 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results